NCT01362231 - A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

GS-6624

Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.

Trial Locations (7)

UPMC Translational Research Center, Pittsburgh

Medical University of South Carolina, Charleston

Vanderbilt University Medical Center, Nashville

Loess Hills Clinical Research Center, Council Bluffs

Arizona Pulmonary Specialists, Scottsdale

David Geffen School of Medicine at UCLA, Los Angeles

Stanford University Medical Center, Stanford